Ascletis Announces First Participants With Obesity or Overweight Dosed in Its U.S. 12-Week Phase Iia Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule Glp-1R Agonist Asc30

THOMSON REUTERS
28 Jul

Ascletis Announces First Participants With Obesity or Overweight Dosed in Its U.S. 12-Week Phase Iia Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule Glp-1R Agonist Asc30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10